Refine by MP, party, committee, province, or result type.

Results 1-9 of 9
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  I would very strongly support the idea of tax incentives for investors, but it's a bit more complicated than that. In these labour-sponsored funds in Manitoba, Quebec, and other provinces, they gave tax credits to the private sector. Now some of the private sector investors didn'

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  I can address the MPIC or the single payer. The single payer is the same organization that's paying now, the Department of Health, which is supported by the federal government. So they have provincial and federal support. That's the single payer. I think in that way you can regul

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  There are two things, quickly. One is, as I said, that it's impossible for the health protection branch to have the expertise to really do a good regulatory process of all drugs that the FDA sees. So they should coordinate and work together with the FDA and other agencies and s

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  The TPC was a very successful program. It led to a number of companies, Neurocan and others, becoming fairly successful, and a lot of products. In basic research, there are some good programs. One of the things I would very quickly say is that changing is a problem. CFI is a grea

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  I was going to give the example but didn't have time. For example, when we got WinRho approved in 1980, the Province of Manitoba immediately switched from Johnson & Johnson's RhoGAM product to WinRho. Next was Saskatchewan, Alberta, Quebec—interestingly enough—and I think the

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  No, I was just finishing my Ph.D.; I hadn't quite finished. So he had that idea. In the interview, I asked him what the future was—an idea, a publication...? He said, “What you make of it.” That's what his answer was. I was fortunate to be maybe naive and somewhat optimistic, an

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  I have one minute? Amgen and Genentech are among the largest biotech companies. In both cases, the science was matched with a business entrepreneur. That didn't happen in the case of Dr. Harley. Dr. Chown was entrepreneurial; I was fortunate to be entrepreneurial. So I'm back

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  Thank you, and thank you for the opportunity. It's much appreciated.

May 23rd, 2013Committee meeting

Dr. Albert Friesen

Health committee  Again, thank you to the committee and to you for this opportunity to share. Health innovation has been a lifelong interest of mine. Actually, I think it's a calling and a passion. This is actually the first time I've organized some of my thoughts from over the past 40 years.

May 23rd, 2013Committee meeting

Dr. Albert Friesen